Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Alzheimer's Medication Trials

New York

Alzheimer's medication trials in New York

26 Alzheimer's medication studies are recruiting participants at sites in 16 cities across New York as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5916
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every New York city with a recruiting study

New York (11), Syracuse (5), Albany (4), Woodmere (4), New Windsor (3), Buffalo (2), Laurelton (2), Staten Island (2), Amherst (1), Brooklyn (1), Manhasset (1), Orangeburg (1), Queens (1), Rochester (1), Rosedale (1), Valley Stream (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in New York

Basic details from each study's public record (the 12 most recently updated of 26). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Albany · Amherst · Buffalo
    Registry record
    NCT06976203 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    New York · Syracuse
    Registry record
    NCT06976216 · updated
  3. Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

    • Phase 2
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Laurelton
    Registry record
    NCT07781657 · updated
  4. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Woodmere
    Registry record
    NCT05980949 · updated
  5. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Recruiting in
    New York
    Registry record
    NCT06887192 · updated
  6. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Woodmere
    Registry record
    NCT07011732 · updated
  7. Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

    • Phase 2/3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Exciva GmbH
    Recruiting in
    Brooklyn · New York
    Registry record
    NCT07284472 · updated
  8. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    • Phase 3
    • Ages 55 to 80
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Laurelton
    Registry record
    NCT07717411 · updated
  9. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Recruiting in
    Syracuse
    Registry record
    NCT06159673 · updated
  10. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Staten Island · Valley Stream
    Registry record
    NCT07011745 · updated
  11. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    New Windsor · Syracuse · Woodmere
    Registry record
    NCT06585787 · updated
  12. [18F]PI-2620 Phase 3 Histopathological Study

    • Phase 3
    • Ages 50 and older
    • All sexes
    Sponsor
    Lantheus Biosciences Ltd.
    Recruiting in
    Syracuse
    Registry record
    NCT05641688 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in New York on ClinicalTrials.gov.

Ask about studies in New York

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

Alzheimer's Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5916

or send a short form

How should we reach you?

Call